CA2177570A1 - Method of treating intestinal disorders - Google Patents

Method of treating intestinal disorders

Info

Publication number
CA2177570A1
CA2177570A1 CA002177570A CA2177570A CA2177570A1 CA 2177570 A1 CA2177570 A1 CA 2177570A1 CA 002177570 A CA002177570 A CA 002177570A CA 2177570 A CA2177570 A CA 2177570A CA 2177570 A1 CA2177570 A1 CA 2177570A1
Authority
CA
Canada
Prior art keywords
tnf
agent
bile
production
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002177570A
Other languages
English (en)
French (fr)
Inventor
Graham Douglas Fischer Jackson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Unisearch Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPM8325A external-priority patent/AUPM832594A0/en
Application filed by Unisearch Ltd filed Critical Unisearch Ltd
Publication of CA2177570A1 publication Critical patent/CA2177570A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002177570A 1993-12-01 1994-12-01 Method of treating intestinal disorders Abandoned CA2177570A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPM274093 1993-12-01
AUPM2740 1993-12-01
AUPM8325 1994-09-21
AUPM8325A AUPM832594A0 (en) 1994-09-21 1994-09-21 Bile tnf

Publications (1)

Publication Number Publication Date
CA2177570A1 true CA2177570A1 (en) 1995-06-08

Family

ID=25644589

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002177570A Abandoned CA2177570A1 (en) 1993-12-01 1994-12-01 Method of treating intestinal disorders

Country Status (4)

Country Link
EP (1) EP0732938A4 (de)
JP (1) JPH09505812A (de)
CA (1) CA2177570A1 (de)
WO (1) WO1995015179A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0585705B1 (de) * 1992-08-28 1998-11-04 Bayer Corporation Verwendung von monoklonalen Anti-TNF-Antikörpern für die Behandlung von bakteriellen Meningitiden
JP3499562B2 (ja) * 1993-09-24 2004-02-23 アドヴァンスト・イミューニット・インク Ｃｒｏｈｎ’ｓ病および／または潰瘍性大腸炎の治療もしくは予防
AU770726B2 (en) * 1998-10-20 2004-02-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of a cytokine-producing lactococcus strain to treat colitis
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US20130165399A1 (en) 2010-06-18 2013-06-27 Hayashibara Co., Ltd. Therapeutic agent for inflammatory diseases, containing adenosine n1-oxide as an effective ingredient

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8805792D0 (en) * 1988-03-11 1988-04-13 Celltech Ltd Medicaments
AU4182289A (en) * 1988-08-19 1990-03-23 Celltech Limited Pharmaceutical products for anti-neoplastic therapy
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
AU1531492A (en) * 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
EP0732938A1 (de) 1996-09-25
WO1995015179A1 (en) 1995-06-08
JPH09505812A (ja) 1997-06-10
EP0732938A4 (de) 1997-03-19

Similar Documents

Publication Publication Date Title
Patton et al. Development of partial tolerance to the gastrointestinal effects of high doses of recombinant tumor necrosis factor-alpha in rodents.
Alexander et al. A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice.
Curfs et al. Immunological aspects of cerebral lesions in murine malaria.
RU2563179C2 (ru) Составы, содержащие антитела
MacKay et al. Tumor necrosis factor activity in the circulation of horses given endotoxin
JP2010222364A (ja) 大腸炎処置のためのサイトカイン産生性ラクトコッカス株の使用
Mattner et al. Treatment with homodimeric interleukin-12 (IL-12) p40 protects mice from IL-12-dependent shock but not from tumor necrosis factor alpha-dependent shock
Michie et al. Sepsis, signals, and surgical sequelae (a hypothesis)
JP7386455B2 (ja) 乾癬の治療薬
WO2021143912A1 (zh) 无细胞脂肪提取液对脂肪肝及其并发症的治疗作用
WHERRY et al. Tumor necrosis factor and the therapeutic potential of anti-tumor necrosis factor antibodies
DE60003152T2 (de) Tumor nekrose faktor antagonisten und ihre verwendung gegen endometriose
Lange et al. Immunodysfunction in acute-on-chronic liver failure
Remick et al. Pathophysiologic alterations induced by tumor necrosis factor
Mayoral et al. Decreased tumor necrosis factor production during the initial stages of infection correlates with survival during murine gram-negative sepsis
CA2177570A1 (en) Method of treating intestinal disorders
JP2017514875A (ja) 失禁および他の括約筋不全障害を処置する方法
TWI828155B (zh) 吡咯并嘧啶類化合物的用途
US6613741B2 (en) Method for treating aseptic SIRS in humans and other animals
WO2003046008A1 (en) Therapeutic use of antibodies and fragments thereof binding primate ifn-gamma
Michie et al. Sepsis and tumor necrosis factor--bedfellows that cannot be ignored.
WO2016075687A2 (en) Attenuated or inactivated pathogenic escherichia coli for treating urogenital cancer
CN113613644A (zh) 胃肠疾病及其症状的治疗
May et al. Identification of tumour necrosis factor in the blood and peritoneal fluid of horses with colic
Li et al. Treadmill training improves neural function recovery in rats with spinal cord injury via JAK2/STAT3 signaling pathway and attenuating apoptosis

Legal Events

Date Code Title Description
FZDE Dead